Abstract: Derivatives of simple monosaccharides which exhibit anti-proliferative and/or anti-inflammatory activity and are useful for treating mammals having inflammatory disorders and/or autoimmune disorders. This invention also encompasses pharmaceutical compositions containing these compounds and methods of treating inflammatory and/or autoimmune disorders.

Abstract: An anhydrous, topically-effective composition that resists phase separation and exhibits improved properties comprising a topically-active compound, such as an astringent salt; an improved suspending agent comprising a finely-divided silica and a suspending wax composition; and a suitable volatile liquid carrier, such as a volatile silicone or a volatile hydrocarbon. The suspending wax composition comprises a wax, an ester including at least 10 to about 32 carbon atoms and a volatile liquid carrier. The anhydrous, topically-effective composition is useful in topical cosmetic and medicinal preparations, such as antiperspirants, sunscreens and topical drug products, and is especially useful in cosmetic and medicinal preparations wherein an insoluble topically-active compound is dispersed throughout a liquid phase.

Abstract: Compositions containing 1.alpha.-hydroxyvitamin D homolog compounds in a suitable carrier and methods employing such compositions are disclosed for cosmetic uses in the treatment of various skin conditions such as lack of adequate skin firmness, wrinkles, dermal hydration and sebum secretion. Various formulations of the compositions including creams, lotions and ointments are disclosed for use topically, orally or parenterally in accordance with this invention.

Abstract: A medicine for skin diseases contains a fermented and condensed extract from the stems of Stevia Rebaudiana Bertoni as an active ingredient. The medicine is prepared by condensing and fermenting an extract from the ripened stems of Stevia Rebaudiana Bertoni by multi-stage condensation followed by fermentation and ripening of the condensed extract. It is effective for various skin diseases and other diseases caused by blood circulation insufficiency.

Abstract: Aromatic heterocyclic derivatives have the formula ##STR1## wherein R.sub.1 represents (i)--CH.sub.3, (ii)--CH.sub.2 OH or (iii) ##STR2## wherein R.sub.3 represents hydrogen, --OR.sub.4 wherein R.sub.4 represents hydrogen, alkyl having 1-20 carbon atoms or mono- or polyhydroxyalkyl or R.sub.3 represents ##STR3## wherein r' and r" represent hydrogen, lower alkyl or together form a heterocycle, R.sub.2 represents hydrogen or --CH.sub.3 and Ar represents ##STR4## wherein R.sub.6 is hydrogen or alkyl having 1-10 carbon atoms and R.sub.7 represents alkyl having 4-12 carbon atoms or cycloalkyl, Y is CH or a nitrogen atom and X represents oxygen, sulfur or --N--R.sub.8 when R.sub.8 represents hydrogen, lower alkyl or lower alkoxycarbonyl, with the proviso that (i) when Y is CH and X is oxygen or sulfur Ar is other than C and (ii) when Y is nitrogen and X is oxygen, Ar is other than (C) or (D) in which R.sub.6 is alkyl having 1-4 carbon atoms and R.sub.7 is branched alkyl having 4-12 atoms.

Abstract: Therapeutic as well as preventative measures to improve the cosmetic conditions or to alleviate the symptoms of dermatologic disorders with phenyl alpha acyloxyalkanoic acids and derivatives is disclosed. The cosmetic conditions and dermatologic disorders in humans in which the compounds may be useful include brittle or soft nails; abnormally thin skin, mucous membranes or wound; friction blisters; brittle hairs; pruritus; acne; and diseased nails, skin or mucous membranes due to natural or unnatural causes including but not limited to in flammations or infections. The phenyl alpha acyloxyalkanoic acids and derivatives include, for example, diphenyl alpha acetoxyacetic acid, phenyl alpha acetoxyacetic acid, phenyl alpha methyl alpha acetoxyacetic acid and phenyl alpha acetoxypropanoic acid. The compositions containing the active ingredients are also useful for treatment of skin, nails and hair conditions or disorders in domestic animals.

Abstract: This invention provides compositions comprising a physiologically-active agent and a compound having the structural formula ##STR1## wherein X may represent sulfur or two hydrogen atoms; R' is H or a lower alkyl group having 1-4 carbon atoms; m is 2-6; n is 0-18 and R is --CH.sub.3, ##STR2## wherein R" is H or halogen, in an amount effective to enhance the penetration of the physiologically-active agent through the skin or other membrane of the body of an animal.

Abstract: A skin lotion and methods of use involving a skin lotion comprising effective amounts of allantoin, castor oil, oleic acid, calcium hydroxide powder and witch hazel water. The methods of use include as a keratoplastic and keratolytic for removing the "piled up" hyperkeratotic scales in seborrheic capitis and psoriasis vulgaris; to expedite the involution of the lesions of acute herpes simplex.

Abstract: The invention refers to compounds having activity against inflammatory, allergic, and dermatological conditions. The compounds are characterized by the formula ##STR1## or a stereoisomeric component thereof, in which formula R.sub.1 is selected from a straight or branched hydrocarbon chain having 1-4 carbon atoms.The invention also refers to processes for the preparation of these compounds, pharmaceutical preparations containing one of the compounds and a method for the treatment of inflammatory, allergic, muscoskeletal and dermatological conditions.

Abstract: Treatment of an animal with calcium flux inhibitors results in a decrease in the number of epidermal Langerhans cells and a simultaneous decrease in the ability to respond to contact sensitizing agents. Also, topical application of calcium flux inhibitors will reduce inflammation in patients experiencing delayed-type hypersensitivity reaction or atopic eczema. Thus, calcium flux inhibitors represent a new class of therapeutic agents in the treatment of contact dermatitis and eczema.

Abstract: A method of treating patients having chronic, severe allergic disorders, such as atopic dermatitis or steroid-dependent asthma, with gamma interferon is disclosed. The method involves treating patients afflicated with atopic dermatitis or steroid-dependent asthma with effective dosages of gamma interferon, which reduces the clinical severity of their disease.

Abstract: Disclosed are a bath lotion and a body lotion both consisting essentially of a fermented liquid of high polymer complex polysaccharides. The fermented liquid is obtained by activating and heat-treating a xanthane gum with microorganisms for carbohydrate fermentation. The bath lotion and body lotion are effective and advantageous to health and have a pharmaceutical effect.

Abstract: Ozonides of terpenes are disclosed. Terpenes which are believed to be pharmacologically active when prepared in accordance with the present invention include: limonene, citronella, alpha-carotene, beta-carotene, Vitamin A, linalool, linalyl acetate, or squalene. Other compounds which are believed to make pharmacologically active terpene ozonides in accordance with the present invention include geraniol, limonene, alpha-pinene, loganin, cymene, farnesanes, eudesmanes, acoranes, cedranes, chamigranes, caryophyllanes, illudanes, humulenes, himachalenes, longifolanes, perhydroazulenes, quaianes, quaianolides, or germacranes. Still other compounds which are believed to make pharmacologically active terpene ozonides in accordance with the present invention include labdanes, clerodanes, abietic acid, phyllocladene, giberellins, ophiobolin A, retigeranic acid, gasgardic acid, lanosterol, euphol, oleanane, ursane, lupeol, hydroxyhopanone, lupanes, or hopanes.

Abstract: A method of inhibiting phospholipase A2 in the control of inflammation, wherein delta-6,9,12,15-octadecatetraenoic acid (stearidonic acid) and/or delta-8,11,14,17-eicosatetraenoic acid is administered alone or in a pharmaceutically acceptable diluent or carrier.

Abstract: It has been discovered that 6-(substituted amino)purine cytokinins, such as kinetin, induce differentiation, and consequently reduce or eliminate the abnormally high rate of proliferation, of hyperproliferating cells associated with hyperproliferative skin diseases. Thus, the present invention provides methods and compositions for treating hyperproliferative skin diseases in mammals, particularly such diseases associated with hyperproliferating epidermal cells in humans, by administering to the hyperproliferating cells associated with such a disease, in the skin of a mammal suffering therefrom, a differentiation-inducing effective amount of a 6-(substituted amino)purine cytokinin.

Abstract: Some polyunsaturated acids (ximeninic acid, .gamma.-homo-linolenic acid, eicosapentaenoic acid), suitably formulated and administered by the topical route, possibly in form of glicerids or of complexes with phospholipids, have vasokinetic and vasodilative properties.

Abstract: The invention relates to combination preparations containing chloramphenicol, gentamicin, nystatin and optionally a cortisone as active ingredients for the topical treatment of inflammatory skin disorders. The preparations are present preferably in the form of an ointment and have proved to be surprisingly effective particularly in the case of the treatment of skin disorders which are difficult to heal such as chronic eczema, inflammations in the anal and genital region, and of ulcus cruris and similar disorders.

Abstract: Diarylacetylenes of the formula I ##STR1## where R.sup.1 is hydrogen or C.sub.1 -C.sub.4 -alkyl, R.sup.2 and R.sup.3 are each hydrogen or, when R.sup.1 is hydrogen, together form a --C(CH.sub.3).sub.2 --B--C(CH.sub.3).sub.2 -- group (where B is --CH.sub.2 Ch.sub.2 -- or --CH(CH.sub.3)--) or --OC(Ch.sub.3) (Z)CH.sub.2 CH.sub.2 -- group (where Z is C.sub.1 -C.sub.2 -alkyl) or R.sup.2 is C.sub.1 -C.sub.3 -alkoxy and R.sup.3 is C.sub.1 -C.sub.10 -alkyl or, when R.sup.2 is hydrogen, R.sup.1 and R.sup.3 are each alkyl as defined above, R.sup.4 is C.sub.1 -C.sub.6 -alkyl and n is 0, 1 or 2, are prepared as described and used as active compounds in drugs and cosmetics.

Abstract: An external adhesive preparation comprising a steroid for treatment of skin diseases in admixture with an adhesive gel base comprising as essential components a water-soluble high molecular weight compound, water and a water-retaining agent. The external adhesive preparation is useful for treatment of skin diseases by applying the preparation spread on a soft support directly to diseased parts on the skin, thereby administering the contained steroid to the skin.

Abstract: Compounds of formula I ##STR1## wherein R.sup.1 and R.sup.2 are each hydrogen or methyl, A is an ethylene or methylene radical which is unsubstituted or substituted by methyl, hydroxyl or oxo, L is a saturated or unsaturated five-membered or six-membered heterocyclic structure which is unsubstituted or substituted by hydroxyl, mercapto, C.sub.1 -C.sub.6 -alkyl, or C.sub.1 -C.sub.4 -alkanoyl and has from 1 to 3 heteroatoms from the group consisting of N, O and S, the second and third heteroatoms being a nitrogen atom,R.sup.3 is hydrogen, a hydroxy or C.sub.1 -C.sub.6 -alkoxy group,R.sup.4 is hydrogen, C.sub.1 -C.sub.4 -alkyl, halogen or methoxy,R.sup.5 is hydrogen or methoxy or tert-butyl,R.sup.6 is hydrogen, methyl, nitrile or a C.sub.2 -C.sub.10 -ketal group or the radical --CHR.sup.7 OR.sup.8 --CHR.sup.7 --NR.sup.9 R.sup.10, --COR.sup.11, --SR.sup.12, ##STR2## in which R.sup.7 is hydrogen or C.sub.1 -C.sub.4 -alkyl,R.sup.8 is hydrogen, C.sub.1 -C.sub.4 -alkyl or C.sub.1 -C.sub.

Abstract: Certain compounds having sesquiterpene structures, when combined with monocarboxylic fatty acids, esters or amides, have efficacy in the treatment of papulosquamous and eczematous diseases. Prime examples of the sesquiterpene compounds are artemisinin and analogs, and prime examples of the monocarboxylic fatty acid compounds are lauric acid, monolaurin and lauryl-N,N-dimethylamide.

Abstract: This invention relates to activated protein-containing compositions comprising reducing agents, oxidizing agents and/or anti-oxidants and methods of use. The therapeutic compositions and methods of the present invention are particularly effective in promoting wound healing, and in inhibiting certain skin disorders, including eczema and seborrhea, sclerodema and acne. The therapeutic compositions and methods of the present invention have also shown enhanced effect as veterinary tools in reducing the debilitation associated with certain skin conditions in mammals including eczematoid dermatitis, chronic dermatitis, equine exuberant granuloma ("proud flesh"), decubitis ulcers, and canine cutaneous granulomas ("lick" granuloma).

Abstract: Retinoid-like activity is exhibited by compounds of the formula ##STR1## where X is S, O or NR'; where R' is hydrogen or lower alkyl; R.sub.1, R.sub.2 and R.sub.3 are hydrogen or lower alkyl; R.sub.4 and R.sub.5 are hydrogen or lower alkyl with the proviso that R.sub.4 and R.sub.5 cannot both be hydrogen, A is pyridyl, thienyl, furyl, pyridazinyl, pyrimidinyl, pyrazinyl, thiazolyl or oxazolyl; n is 0-5, and B is H, --COOH or a pharmaceutically acceptable salt, ester or amide thereof, --CH.sub.2 OH or an ether or ester derivative, or --CHO or an acetal derivative, or --COR.sub.1 or a ketal derivative where R.sub.1 is --(CH.sub.2).sub.m CH.sub.3 where m is 0-4, or a pharmaceutically acceptable salt thereof.

Abstract: A therapeutic composition for the treatment of skin disorders comprises a therapeutically effective amount of a curative agent chosen from special esters of pyroglutamic acid, and mixtures thereof, in a therapeutically acceptable vehicle for topical application.

Abstract: Methods for increasing extracellular concentrations of adenosine for the prophylactic or affirmative treatment of diseases of the immune, nervous, cardiac, and vascular systems involving administering to a patient purine nucleoside and purine nucleoside-related analogs which increase extracellular adenosine concentration, and methods for stabilizing mast cells by the suppression of mast cell activation using such compounds.

Abstract: p-Alkyl or cycloalkyl phenoxy alkanols and esters are provided having the structure: ##STR1## in which: R.sub.1 is an alkyl group having from one to six carbon atoms, preferably tertiary, and still more preferably tertiary-butul; or a bivalent cycloalkylene group condensed with the phenyl group at adjacent ring carbons thereof, such as in indane;R.sub.2 is lower alkyl having from one to three carbon atoms or hydrogen;R.sub.3 is hydroxyl or an ester group selected from the group consisting of COOR.sub.4 and OOCR.sub.4 derived from unsubstituted and hydroxy-substituted monocarboxylic acids and COOR.sub.5 OOC and OOCR.sub.

Abstract: Aryl-substituted naphthyridines and pyridopyrazines are disclosed which are useful in treating allergic reactions, inflammation, peptic ulcers and/or hyperproliferative skin disease. Pharmaceutical compositions and methods of treatment employing such compounds are also disclosed.

Abstract: Derivatives of 1,2-O-isopropylidene-.alpha.,D-glucofuranose and intermediates for preparing these derivatives are described. These derivatives are useful for treating animals and mammals with inflammatory and/or autoimmune disorders such as autoimmune deficiency syndrome, psoriasis, atopic dermatitus, rheumatoid arthritis, osteoarthritis, scleroderma and systemic lupus erythematosus.

Abstract: Medicinal and cosmetic compositions for the treatment of skin disorders and for care of dry and/or irritated skin and of dry scalp with dandruff are prepared using brewers' grains extract(s)--especially a brewers' grains extract obtained using liquid or above-critical CO.sub.2 or N.sub.2 O.

Abstract: Personal care products comprising bioemulsifiers, for example, those produced by Acinetobacter calcoaceticus, are provided. Use of such personal care products result in beneficial effects to skin and hair.

Abstract: Derivatives of -.alpha.,D-glucofuranose .alpha.,D-allanfuranose and intermediates for preparing these derivatives are described. These derivatives are useful for treating animals and mammals with inflammatory and/or autoimmune disorders such as psoriasis, atopic dermatitus, rheumatoid arthritis, osterarthritis, scleroderma and systemic lupus erythematosus.

Abstract: A composition for treatment and treatment of certain skin diseases is disclosed. The treatment combines furocoumarins, UV-A radiation, and a benzylidene-camphor derivative. The composition and treatment produces the desirable results of the furocoumarin/UV-A radiation treatment without the undesirable phototoxic side effects.

Abstract: A complex based on anthralin and a sterol, characterized in that its melting point is 10 to 25 degrees Celsius lower than that of the constituent of the complex melting at the lowest temperature and that the proportion of anthralin varies between 10 and 90 mol %.

Abstract: A degreasing or moisturizing composition contains silanized silica gel, a humectant such as glycerine, and an inert carrier. The composition is used to treat sebhorreic conditions without causing dry skin.

Abstract: The present invention is directed to a pharmaceutical preparation for external or transdermal application which comprises a dispersion of liposomes, wherein said liposomes incorporate or enclose an active ingredient.

Abstract: The invention concerns compositions with antimicrobial activity.These compositions contain a benzoic acid derivative with the formula: ##STR1## in which: A represents a straight or branched alkyl chain with 3 to 4 carbon atoms,X represents the oxygen atom or a direct bond,R represents hydrogen or an alkyl group with 2 to 6 carbon atoms, possibly substituted by an alcohol function and a salt of such a derivative.Applications: drugs, disinfectants and preservative agents.

Abstract: A cosmetic composition for the treatment of the hair and skin comprises at least 5 weight percent of pulverized particles of at least one plant. The particles have a granulometry lower than 125 microns. The compositions also includes a cohesion agent in an amount to maintain the homogeneity of the composition.

Abstract: There is described a medicinal bath oil containing about 68-95 percent by weight of one or more physiologically acceptable oil and about 30-5 percent by weight of one or more physiologically acceptable emulsifiers, at least one of which is a fatty alcohol polygolyol ether.

Abstract: Aromatic heterocyclic derivatives have the formula ##STR1## wherein R.sub.1 represents (i)--CH.sub.3, (ii)--CH.sub.2 OH or (iii) ##STR2## wherein R.sub.3 represents hydrogen, --OR.sub.4 wherein R.sub.4 represents hydrogen, alkyl having 1-20 carbon atoms or mono- or polyhydroxyalkyl or R.sub.3 represents ##STR3## wherein r' and r" represent hydrogen, lower alkyl or together form a heterocycle, R.sub.2 represents hydrogen or --CH.sub.3 and Ar represents ##STR4## wherein R.sub.6 is hydrogen or alkyl having 1-10 carbon atoms and R.sub.7 represents alkyl having 4-12 carbon atoms or cycloalkyl, Y is CH or a nitrogen atom and X represents oxygen, sulfur or --N--R.sub.8 when R.sub.8 represents hydrogen, lower alkyl or lower alkoxycarbonyl, with the proviso that (i) when Y is CH and X is oxygen or sulfur Ar is other than C and (ii) when Y is nitrogen and X is oxygen, Ar is other than (C) or (D) in which R.sub.6 is alkyl having 1-4 carbon atoms and R.sub.7 is branched alkyl having 4-12 atoms.

Abstract: A process for preparing a dermatological lotion comprises sequentially adding 160 to 240 g. salicylic acid, 160 to 240 g. alum powder and 45 to 55 tincture of iodine to 800 to 1200 ml. ethyl alcohol to provide a mixture, homogenizing the mixture, and then maintaining the homogenized mixture quiescent for at least one week.

Abstract: Methods for increasing extracellular concentrations of adenosine for the prophylactic or affirmative treatment of diseases of the immune, nervous, cardiac, and vascular systems involving admimistering to a patient purine nucleoside and purine nucleoside-related analogs which increase extracellular adenosine concentration, and methods for stabilizing mast cells by the suppression of mast cell activation using such compounds.

Abstract: Compounds of Formula I ##STR1## the pharmaceutically acceptable salts, and the gamma-lactone form thereof are described. They are antagonists of leukotrienes and SRS-A.

Abstract: Provided is a cosmetic compositiom which beautifies and moisturizes the skin of a human being. The composition may also have therapeutic effects on the human skin such as the removal of lines or wrinkles, dissolution of fat pockets, the removal of bags under the eyes, and the closing of pores or gaps in the skin to render a smooth uniform appearance. The composition is comprised of seven basic ingredients, which include:live yeat cells,selenium,carotene,RNA,DNA,water andalbumen.These core ingredients generally make up from about 80% to 100% of the composition used in the treatment, and are the basis for the advantages realized thereby. Significant and long-lasting results are particularly achieved upon application of the composition to the human skin with exposure to sunlight.

Abstract: The compound 6-acetyl-7-[5-(4-acetyl-3-hydroxy-2-propylphenoxy)pentyloxy]-3,4-dihydro-2 4-1-benzopyran-2-carboxylic acid, as well as its enantiomers, salts and lower alkyl esters, are useful in topically administrable dosage forms for the treatment of leukotriene-mediated dermal inflammations, such as psoriasis. These compounds can be formulated into creams, ointments, lotions, gels and other types of compositions suitable for applying on the skin.

Abstract: A cosmetic composition for the treatment of the hair and skin comprising, in an aqueous medium, particles of pulverized flowers or flower tops having a granulometry lower than 125 microns and a cohesion agent present in an amount effective to maintain the homogeneity of the composition. The cohesion agent can be a thickening agent, a water-in-oil emulsion or an oil-in-water emulsion.

Abstract: Personal care products comprising bioemulsifiers, for example, those produced by Acinetobacter calcoaceticus, are provided. Use of such personal care products result in beneficial effects to skin and hair.

Abstract: Noninfectious inflammatory skin diseases in which bacteria or yeasts play a significant adjunctive role are treated with topical formulations of aliphatic amines containing 9 to 18 carbon atoms, and pharmaceutically acceptable salts thereof.

Abstract: A method of treatment of atopic disorders, including eczema, asthma, allergies (especially allergic rhinitis), migraine and disorders associated with atopy including Crohn's disease, ulcerative colitis, otitis media, nephrotic syndrome, or benign breast disease, or breast or other cancer, or diabetes, or alcoholism, with effective amounts of one or more of the metabolites of linoleic acid (GLA, DGLA, AA, 22:4n-6 or 22:5n-6) and one or more of the metabolites of .alpha.-linolenic acid (18:4n-3, 20:4n-3, 20:5n-3, 22:5n-3 or 22:6n-3) are administered as such or in the form of an ester, salt, amide or other derivative convertible in the body thereto alone or in an acceptable pharmaceutical carrier or diluent.

Abstract: Cosmetic and dermatological compositions containing 1.alpha.-hydroxycholeciferol and a suitable carrier useful in topical treatment of skin disorders and methods employing same are disclosed. Compositions containing 1.alpha.,25-dihydroxycholecalciferol and a suitable carrier and methods employing same are also disclosed for dermatological and cosmetic uses. Various formulations of the compositions including creams, lotions, ointments and sprays are disclosed for use in accordance with this invention. The compositions and formulations may contain additional active ingredients.

Abstract: A cosmetic composition for the treatment of the hair and skin comprising, in an aqueous medium, particles of pulverized flowers or flower tops having a granulometry lower than 125 microns and a cohesion agent present in an amount effective to maintain the homogeneity of the composition. The cohesion agent can be a thickening agent, a water-in-oil emulsion or an oil-in-water emulsion.